<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VARICELLA VACCINE</span><br/>(var-i-cel'la)<br/><span class="topboxtradename">Varivax<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">vaccine</span>; <span class="classification">viral</span><br/><b>Prototype: </b>Hepatitis B<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1350 PFU/vial</p>
<h1><a name="action">Actions</a></h1>
<p>A live attenuated vaccine that acts against both chickenpox and shingles, both of which are caused by <i>Varicella zoster</i> infection.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Protects healthy children and adults from varicella effectively.</p>
<h1><a name="uses">Uses</a></h1>
<p>Vaccination against varicella in individuals <img src="../images/special/greaterorequal.gif"/>12 mo.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component of the vaccine; history of anaphylactoid reaction to neomycin; individuals with blood dyscrasia,
         leukemia, lymphomas, bone marrow or lymphatic system malignancies, concomitant immunosuppression therapy; individuals with
         primary or acquired immunodeficient states; active untreated tuberculosis; any febrile respiratory illness or other febrile
         infections; lactation; pregnancy (category C); children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Acute lymphoblastic leukemia in remission.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Varicella Protection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> Primary immunization of 0.5 mL followed by 0.5 mL 48 wk after first dose, may need to revaccinate 3 mo after initial
               series if patient fails to seroconvert<br/><span class="rdage">Child:</span> <span class="rdroute">SC</span> <i>12 mo12 y</i>, Single dose of 0.5 mL<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute vaccine with 0.7 mL of supplied diluent; gently agitate the vial to mix. Withdraw entire contents of vial (0.5
            mL) into syringe for injection. Change needle on syringe and administer immediately or within 30 min of reconstitution.
         </li>
<li>Give SC into the outer aspect of the deltoid. Exercise caution not to inject IV.</li>
<li>Store powder vaccine in frost-free freezer at 15° C (+5° F) or colder. Store diluent separately at room temperature
            or in the refrigerator.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, fever. <span class="typehead">Hematologic:</span> Mild thrombocytopenia. <span class="typehead">Skin:</span> <span class="speceff-common">Redness, swelling, or rash at injection site</span>. <span class="typehead">Other:</span> Herpes zoster infection (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Acyclovir</b> decreases vaccine's effectiveness. It is recommended that <b>yellow fever vaccine</b> be given at least 1 mo apart from varicella or any other live virus vaccine. Avoid <b>salicylates</b> for 6 wk after vaccination to decrease risk of developing Reye's syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Seroconversion approximately 42 d after vaccination. <span class="typehead">Duration:</span> &gt;510 y in healthy children. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold vaccine and notify physician if patient has a history of hypersensitivity to neomycin or a current febrile infection.</li>
<li>Monitor for signs and symptoms of hypersensitivity (see Appendix F) and administer epinephrine if an anaphylactoid reaction
            occurs.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid use of salicylates (e.g., acetylsalicylic acid) for 6 wk after vaccination, especially with children and adolescents.</li>
<li>Notify physician about all adverse reactions (i.e., fever, rash, respiratory illness).</li>
<li>Do not breast feed after taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>